REGENXBIO Launches a Manufacturing Facility for Developing Gene Therapies Based on NAV-Technology

 REGENXBIO Launches a Manufacturing Facility for Developing Gene Therapies Based on NAV-Technology

REGENXBIO Launches a Manufacturing Facility for Developing Gene Therapies Based on NAV-Technology

Shots:

  • REGENXBIO plans to construct a cGMP manufacturing facility in Rockville, Maryland to produce gene therapy vectors based on NAV technology at scales up to 2,000L using its platform suspension cell culture process
  • The addition of new cGMP manufacturing facility complements current external manufacturing capabilities, enabling a supply of NAV vectors from both internal and external sources meeting global regulatory requirements and is expected to be operational in 2021
  • REGENXBIO’s NAV technology is a gene delivery platform contains an exclusive right to 100+ novel AAV vectors including AAV7, AAV8, AAV9 and AAVrh10 and is used to develop therapies for multiple indications

Click here to read full press release/ article | Ref: REGENXBIO | Image: Solebury Trout Access

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post